Subcutaneous Ig NextGen 16% in PID Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Primary Immunodeficiency (PID)
Interventions
DRUG

IgNextGen 16%

IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12

Trial Locations (12)

2031

Sydney Children's Hospital, Randwick

2305

John Hunter Hospital, New Lambton Heights

2605

The Canberra Hospital, Garran

3052

Royal Children's Hospital, Melbourne

5000

Royal Adelaide Hospital, Adelaide

5006

Women's & Children's Hospital, North Adelaide

Unknown

Frankston Hospital, Frankston

Princess Margaret Hospital for Children, Perth

Auckland Hospital, Auckland

Starship Children's Hospital, Auckland

Christchurch Hospital, Christchurch

Wellington Hospital, Wellington

All Listed Sponsors
lead

CSL Limited

INDUSTRY

NCT00391131 - Subcutaneous Ig NextGen 16% in PID Patients | Biotech Hunter | Biotech Hunter